Cartalax
Research OnlyA synthetic tripeptide (Ala-Glu-Asp) from Vladimir Khavinson's bioregulator framework, proposed to support cartilage tissue repair and chondrocyte function. All research originates from Russian institutes with no independent Western validation or controlled human clinical trials.
AED peptide · Ala-Glu-Asp · cartilage bioregulator
Preclinical evidence only
- Preclinical
- 63%
- Human research
- 0%
Based on 8 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
The proposed mechanisms of Cartalax are based entirely on Russian bioregulator research. No independent Western validation or controlled human clinical trials exist.
How It Works (Simplified)
Cartalax is proposed to target cartilage tissue through peptide bioregulation:
Short tripeptide (AED) proposed to penetrate cell membranes and interact with DNA/chromatin in chondrocytes.
Proposed upregulation of ECM synthesis genes (collagen, proteoglycans) and proliferation markers (Ki-67, CD98hc).
Proposed inhibition of MMP-9, an enzyme that degrades cartilage extracellular matrix.
Proposed reduction of cellular aging markers (p16, p21, p53) and upregulation of longevity-associated SIRT-6.
Note: These pathways are theoretical and based on in-vitro/animal studies from a single research group. No human pharmacological validation exists.
Key Research: Linkova N et al. IJMS 2023;24(9):8415
Important Limitations
- 100% of published research originates from Russian institutes (primarily Khavinson’s group at St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication of any Cartalax-specific findings
- No controlled human clinical trials — all evidence is preclinical (cell culture and animal models)
- The bioregulator framework’s proposed mechanism (short peptides interacting with DNA) remains unvalidated by mainstream molecular biology
- Do not confuse with Epithalon (AEDG) — different peptide with different proposed targets despite similar sequence
- No human pharmacokinetic, dosing, or safety data exists
Net effect.Proposed cartilage tissue maintenance — theoretical, from in-vitro/animal work by a single research group.
Theoretical: Peptide-DNA interactions begin at cellular level. No measurable effects expected. Based on bioregulator framework claims — no human pharmacokinetic data exists.
Theoretical: Gene expression changes in target tissues may begin. Proposed upregulation of ECM synthesis pathways. Based on cell culture studies only.
Theoretical: Accumulated effects on cartilage matrix may become relevant. Russian protocols suggest this timeframe for tissue-level changes. No controlled human data.
Theoretical: Maximal proposed benefit window per Khavinson bioregulator framework. No long-term human safety or efficacy data available.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct targets — Cartalax for cartilage/chondrocytes, Epithalon for pineal/telomerase. Often referenced together in Russian bioregulator protocols. Note: Cartalax (AED) shares three of four amino acids with Epithalon (AEDG) but targets different tissues.
BPC-157
CompatibleDifferent mechanisms for connective tissue support. BPC-157 has broader tissue repair evidence from non-Russian research. No known pharmacological interaction.
TB-500
CompatibleComplementary tissue repair mechanisms. TB-500 (thymosin beta-4) promotes cell migration and tissue remodeling. No known interaction with short bioregulator peptides.
Sigumir
CompatibleBoth target cartilage/joint tissue in the bioregulator framework. Sigumir is a cytamin-class complex extract; Cartalax is a defined tripeptide. Often paired in Russian cartilage protocols.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Cartalax
Related Peptides
GHK
Glycyl-Histidyl-Lysine · GHK tripeptide · Liver cell growth factor
A naturally occurring tripeptide (Gly-His-Lys) with copper-binding affinity and wound healing properties. The base form of GHK without added copper. Endogenous to human plasma where it circulates bound to copper. Declines with age. Most research focuses on the copper-complexed form (GHK-Cu), making evidence for GHK alone limited. Primarily relevant as the precursor to GHK-Cu.
GHK-Cu
Copper Peptide GHK · Glycyl-L-Histidyl-L-Lysine:Copper
GHK-Cu is the copper complex of the GHK tripeptide. Cell and animal studies support matrix-remodeling mechanisms, while small topical human studies give mixed results; these findings do not establish injected GHK-Cu efficacy or safety.
Sigumir
Cartilage cytamin · Joint peptides · A-4 cartilage peptides
A cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for joint and cartilage support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Conditions Studied
2 entries- Cartalax for Cartilage Degeneration / Osteoarthritis Cartalax is proposed to support cartilage tissue through chondrocyte gene regulation based on the Khavinson bioregulator framework…
- Cartalax for Age-Related Joint Decline Within the Khavinson bioregulator framework, Cartalax is positioned to address age-related cartilage changes. Russian research pro…